Artivion (NYSE:AORT) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Artivion (NYSE:AORT) issued its earnings results on Monday. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04, Yahoo Finance reports. The business had revenue of $97.43 million during the quarter, compared to analysts’ expectations of $92.30 million. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. During the same quarter in the prior year, the firm earned $0.02 EPS. Artivion updated its FY 2024 guidance to EPS.

Artivion Trading Down 1.9 %

NYSE AORT opened at $23.33 on Thursday. Artivion has a one year low of $12.16 and a one year high of $25.51. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.85 and a quick ratio of 3.43. The business has a 50 day simple moving average of $20.57 and a 200 day simple moving average of $18.18. The stock has a market capitalization of $961.20 million, a P/E ratio of -31.11 and a beta of 1.66.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AORT. Needham & Company LLC lifted their target price on Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Stifel Nicolaus upped their price objective on shares of Artivion from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday.

Insiders Place Their Bets

In related news, SVP Marshall S. Stanton sold 2,183 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total transaction of $44,511.37. Following the transaction, the senior vice president now owns 83,296 shares in the company, valued at approximately $1,698,405.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Artivion news, VP Rochelle L. Maney sold 2,315 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $20.27, for a total transaction of $46,925.05. Following the completion of the sale, the vice president now owns 39,197 shares in the company, valued at approximately $794,523.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Marshall S. Stanton sold 2,183 shares of the firm’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total transaction of $44,511.37. Following the completion of the transaction, the senior vice president now directly owns 83,296 shares in the company, valued at $1,698,405.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 149,952 shares of company stock worth $2,891,627. Corporate insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.